ALY688-SR in Generally Healthy Overweight or Obese Adults
NCT ID: NCT04855565
Last Updated: 2021-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
8 participants
INTERVENTIONAL
2021-05-19
2021-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07225556
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
NCT06845943
A Study to Evaluate MWN109 Injection in Healthy Subjects
NCT06859853
A Study of LY3457263 in Obese Participants
NCT05582096
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALY688-SR
single dose subcutaneous injection
ALY688-SR
single dose subcutaneous injection
Matching placebo for ALY688-SR
single dose subcutaneous injection
ALY688-SR
single dose subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALY688-SR
single dose subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
INC Research Australia Pty Ltd
UNKNOWN
Allysta Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ben Snyder, MD
Role: PRINCIPAL_INVESTIGATOR
Nucleus Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALY688-SR-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.